2020-02-04T16:20:15-06:00 2019-06-30 135565207 KPMG LLP 345 PARK AVENUE NEW YORK NY 101540102 990 2018-07-01 135644916 THE LEUKEMIA & LYMPHOMA SOCIETYINC LEUK 9149495213 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 GORDON MILLER JR EVP CHIEF FIN OFFICE 9148218908 2020-02-04 true DAVID M HIGHFILL P01517891 2127589700 2020-02-04 165.225.38.214 2020-02-04 17:19:23 P 64563121E8AEE22D36B9E57E374C7CF58728201C 64563121E8AEE22D36B9E57E374C7CF58728201C 2018 2020-09-23 17:36:50Z LOUIS J DEGENNARO 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 490517231 false X WWW.LLS.ORG X 1949 NY OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. 25 25 1402 3000000 0 419570497 372750094 9230125 14936342 9920211 8619914 133928 -85198 438854761 396221152 157849965 146416708 0 104079229 113204908 5748936 5823217 48650051 88772222 101876640 356450352 367321473 82404409 28899679 382344839 454102204 146112465 185710815 236232374 268391389 X OUR MISSION IS TO CURE LEUKEMIA, LYMPHOMA, HODGKIN'S DISEASE AND MYELOMA, AND IMPROVE THE QUALITY OF LIFE OF PATIENTS AND THEIR FAMILIES. false false 65088628 45038188 14936342 A) RESEARCH PROGRAMS: WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2019, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 44.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. MORE THAN 760 PATIENTS HAVE BEEN SCREENED IN 11 STUDY ARMS AT 16 CANCER CENTERS ACROSS THE COUNTRY. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2019, FOR THE EIGHTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOL 147721907 101378520 B) PATIENT & COMMUNITY SERVICES: PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE- TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2019, 717,119 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 8,621 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 129,388 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2019, A COMBINED 100,656,064 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (97,150,904), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (1,005,560), THE LLS URGENT NEED PROGRAM (1,168,000), AND THE LLS PATIENT AID PROGRAM (1,331,600). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2019, 97,150,904 WAS PROVIDED TO 27,034 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2019, 1,105,560 WAS PROVIDED TO 2202 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2019, 1,168,000 WAS PROVIDED TO 2,357 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2019, 1,331,600 WAS PROVIDED TO 13,316 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2019, 10 BCC CONFERENCES WERE HELD WITH 3,693 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2019, THERE WERE APPROXIMATELY 12,000 COMMUNITY MEMBERS AND 93,212 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 62,050 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2019 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2019, 3,817 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,500 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2019 40007613 C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER. THE NURSES IN THIS CENTER HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2019: - 20,347 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 13,583 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. - 602 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 19 NEARLY 900 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2019: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 10,818 PARTICIPANTS -THERE WERE 29,521 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 2,324 VIRTUAL LECTURE VIEWS; 11,709 PODCAST DOWNLOADS; AND 32,254 VIDEO VIEWS. 13833686 D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2019: -LLS PROVIDED 16 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 3,660 HEALTHCARE PROFESSIONALS IN ATTENDANCE. -THERE WERE 28,877 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 10,602 VIRTUAL LECTURE VIEWS; AND 3,617 ONLINE VIDEO VIEWS FOR PROFESSIONALS. - LLS LAUNCHED A NEW PODCAST "TREATING BLOOD CANCERS" FOR HEALTHCARE PROFESSIONALS. IN ITS' INAUGURAL MONTHS THERE WERE 3,617 DOWNLOADS. 13833686 266651834 true true false true false false false true false true true false false false false true false true false true true true false true true true false true true true false false false false false false false false true false false false true true true true false false true 643 5 true 1402 true false true CA false false false true true false false false false false false X 25 25 false false true false false false false true true false true true true true true true true true true true false AK AL AR AZ CA CO CT DE DC FL GA HI ID IL IN KS KY LA MA MD ME MI MN MO MS NH NJ NM NE NY OH OK OR PA PR RI SC TN UT VA WA WI WV X X GORDON MILLER JR 9148218935 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 LOUIS J DEGENNARO PRESIDENT & 40.00 1.00 X 781916 0 41686 ROSEMARIE A LOFFREDO - END 33119 EVP CHIEF FI 40.00 1.00 X 405232 0 22698 GORDON MILLER JR EVP CHIEF FI 40.00 1.00 X 283759 0 39673 ROBERT BECK - END 7519 EVP CHIEF OP 40.00 1.00 X 256730 0 835 GWEN NICHOLS EVP CHIEF ME 40.00 X 481501 0 38386 ALICE O'ROURKE - END 81518 EVP CHIEF DE 40.00 X 387674 0 31477 KATHY GRIESENBECK EVP CHIEF RE 40.00 X 377786 0 36695 LEE M GREENBERGER SVP CHIEF SC 40.00 X 344708 0 43281 THOMAS OSGOOD EVP CHIEF HU 40.00 X 312125 0 24807 MARCIE KLEIN EVP COMMUNIC 40.00 X 292249 0 35199 ANDREW S COCCARI - END 7618 EVP CHIEF PR 40.00 X 191345 0 26623 JORGE L BENITEZ CHAIRMAN 6.00 2.00 X X 0 0 0 RALPH E LAWSON SECRETARY/TR 4.00 2.00 X X 0 0 0 BART SICHEL VICE CHAIR 4.00 2.00 X X 0 0 0 KATHLEEN MERIWETHER AT LARGE 4.00 X X 0 0 0 WILLIAM G BEHNKE BOD MEMBER 4.00 X 0 0 0 PETER B BROCK BOD MEMBER 4.00 X 0 0 0 A DANA CALLOW JR BOD MEMBER 4.00 X 0 0 0 RENZO CANETTA MD BOD MEMBER 4.00 X 0 0 0 CASEY CUNNINGHAM BOD MEMBER 4.00 X 0 0 0 WILLIAM DALTON - END 10312018 BOD MEMBER 4.00 0.00 X 0 0 0 SAMUEL EBERTS - END 872019 BOD MEMBER 4.00 0.00 X 0 0 0 CHRISTOPHER FLOWERS BOD MEMBER 4.00 X 0 0 0 JANICE GABRILOVE BOD MEMBER 4.00 X 0 0 0 BERNARD H GARIL BOD MEMBER 4.00 X 0 0 0 JOHN GREENE BOD MEMBER 4.00 X 0 0 0 FRANCIE HELLER BOD MEMBER 4.00 X 0 0 0 MICHELLE LE BEAU PHD BOD MEMBER 4.00 X 0 0 0 CONNIE LINDSEY - END 7312018 BOD MEMBER 4.00 X 0 0 0 RUBEN MESA BOD MEMBER 4.00 X 0 0 0 TED MOROZ BOD MEMBER 4.00 X 0 0 0 HARRY MOSELEY - END 1152020 BOD MEMBER 4.00 X 0 0 0 LYNNE O'BRIEN BOD MEMBER 4.00 X 0 0 0 MARLA PERSKY BOD MEMBER 4.00 X 0 0 0 DONALD PROCTOR BOD MEMBER 4.00 X 0 0 0 ROBERT ROSEN BOD MEMBER 4.00 X 0 0 0 STEVEN T ROSEN BOD MEMBER 4.00 X 0 0 0 JEFF SACHS BOD MEMBER 4.00 X 0 0 0 KENNETH M SCHWARTZ BOD MEMBER 4.00 X 0 0 0 KEITH S WHITE BOD MEMBER 4.00 X 0 0 0 4115025 341360 202 true true false SYNEOS HEALTH LLC 75 REMITTANCE DRIVE SUITE 3160 CHICAGO IL 606753160 CLINICAL TRIAL 11379908 TARGETCW 9475 CHESEPAKE DRIVE SAN DIEGO CA 92123 TEMP STAFFING 5932607 RESOURCE ONE 2900 EAST APACHE STREET TULSA OK 74110 DIRECT MARKETIN 5794852 PATIENT ADVOCACY FOUNDATION 421 BUTLER FARM RD HAMPTON VA 23666 PAT ASSIST PROC 4175809 NORTHGATE DIGITAL CORPORATION 301 SOUTH STATE STREET SUITE N-200 NEWTOWN PA 189401956 SOFTWARE DEVELO 3013897 194 946462 191114487 180689145 2792987 372750094 SERVICE REVENUE 14936342 14936342 14936342 7317868 7317868 4512294 4512294 67054315 65752269 1302046 1302046 1302046 23715013 191114487 28271666 -4556653 -4556653 231305 272144 -40839 -40839 396221152 14936342 8534716 39256003 39256003 101378520 101378520 5782185 5782185 2189690 649177 1286985 253528 92000086 50721909 23350599 17927578 2397769 1342200 579851 475718 10371121 5831569 2470049 2069503 6246242 3496461 1510525 1239256 1588548 953129 428908 206511 409901 409901 900103 900103 5823217 5823217 492026 361673 68273 62080 23867423 15065765 5492968 3308690 9777174 4670206 1065057 4041911 19354805 9221114 2759724 7373967 7082941 534054 5261209 1287678 9171449 5857079 1355431 1958939 8414576 5772263 1283222 1359091 4293485 278064 3918615 96806 796510 558247 118868 119395 RESEARCH AND DEVELOPMENT 10467600 10467600 MISCELLANEOUS 5260099 3554513 659403 1046183 367321473 266651834 52019588 48650051 X 12818016 6707110 6110906 26473618 22082281 157894948 239148833 32009273 15172625 2530972 4318740 49903950 40858181 8474228 9045769 145134605 148509455 9827195 10061475 5763026 382344839 454102204 25315604 27935486 105033884 144560351 15762977 13214978 146112465 185710815 X 143923113 174200077 92309261 94191312 236232374 268391389 382344839 454102204 X 28899679 3259336 X false true X true false X 283909984 285638088 314912814 419570497 372750094 1676781477 283909984 285638088 314912814 419570497 372750094 1676781477 287739859 1389041618 1891412 1565846 7018822 8235985 11830162 30542227 56829 19529 25439044 70000 25585402 1732909106 103930407 0.80160 0.76140 X PART II, LINE 10 OTHER MISC. REVENUE (YR 2014-2017) 265,206 TAP CONTRACTUAL RETURN (YR 2016) 25,320,196 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false false true 378846 false true 288980 true 292721 true 709983 1670530 false SCHEDULE C, PART II-B, LINE 1 LLS IS A MEMBER OF A NUMBER OF COALITIONS AND MEMBERSHIPS INCLUDING FRIENDS OF CANCER RESEARCH, ONE VOICE AGAINST CANCER, NATIONAL HEALTH COUNCIL, THE CANCER LEADERSHIP COUNCIL, AMERICAN CHILDHOOD CANCER ORGANIZATION, PUBLIC AFFAIRS COUNCIL, PATIENT QUALITY OF LIFE COALITION, DEFENSE HEALTH RESEARCH CONSORTIUM, AND THE STATE ACCESS TO INNOVATIVE MEDICINES COALITION. LLS PARTNERS WITH LOBBYING FIRMS WHO WORK WITH OUR PUBLIC POLICY STAFF TO CARRY OUT OUR LOBBYING OBJECTIVES. LLS MOBILIZES PATIENT-ADVOCATES AND VOLUNTEERS TO ENGAGE WITH THEIR FEDERAL AND STATE LEGISLATORS THROUGH DIGITAL ADVOCACY - SENDING LETTERS; SHARING THEIR PERSONAL STORIES; SIGNING PETITIONS; AND ENCOURAGING THEIR LEGISLATORS TO SUPPORT LLS' POLICY PRIORITIES. IN CONJUNCTION WITH LLS EMPLOYEES, PATIENT-ADVOCATES ALSO VISIT THEIR LEGISLATORS IN THEIR LOCAL OFFICES, IN WASHINGTON, DC AND IN STATE CAPITOLS TO FURTHER LLS' POLICY AGENDA. X false 6192807 292934 -304999 -12423 6168319 5897377 200 546324 -237896 -13198 6192807 6027967 5200 119369 -240000 -15159 5897377 6115645 45095 116288 -240000 -9060 6027967 6122698 218549 -221499 -4103 6115645 0.46220 0.53780 false false 2342106 1403320 938786 43090674 35880370 7210304 4471170 3574491 896679 9045769 X 418779817 3259336 10371748 9419607 23050691 395729126 492026 492026 396221152 387282901 10371748 10044313 20416061 366866840 492026 -37393 454633 367321473 SCHEDULE D, PAGE 2, PART III, LINE 4 THE LLS COLLECTION IS OF PHOTOGRAPHS WHICH ARE USED FOR PUBLIC EXHIBITION AT FUNDRAISING EVENTS HELD TO SUPPORT LLS'S PROGRAMS. SCHEDULE D, PAGE 2, PART V, LINE 4 LLS'S ENDOWMENTS ARE INTENDED TO FUND RESEARCH AS WELL AS SUPPORT LLS'S PUBLIC EDUCATION PROGRAMS. SCHEDULE D, PAGE 3, PART X LLS, LLSRP, AND LLSRF QUALIFY AS CHARITABLE ORGANIZATIONS AS DEFINED BY INERNAL REVENUE CODE SECTION 501(C)(3) AND, ACCORDING, ARE EXEMPT FROM FEDERAL INCOME TAXES UNDER INTERNAL REVENUE CODE SECTION 501(A). ADDITIONALLY, SINCE THESE ORGANIZATIONS ARE PUBLICLY SUPPORTED, CONTRIBUTIONS QUALIFY FOR THE MAXIMUM CHARITABLE CONTRIBUTION DEDUCTION UNDER THE INTERNAL REVENUE CODE. LLSC IS REGISTERED AS A CHARITABLE ORGANIZATION UNDER THE INCOME TAX ACT (CANADA) AND IS, THEREFORE, NOT SUBJECT TO INCOME TAXES IF CERTAIN DISBURSMEENT REQUIREMENTS ARE MET. LLS AND ITS RELATED ENTITIES RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE TAX POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. INCOME GENERATED FROM ACTIVITIES UNRELATED TO LLS'S EXEMPT PURPOSE IS SUBJECT TO TAX UNDER INTERNAL REVENUE CODE SECTION 511. THERE WERE NO ENTITIES THAT RECOGNIZED ANY UNRELATED BUSINESS INCOME TAX LIABILITY FOR THE YEARS ENDED JUNE 30, 2019 AND 2018. SCHEDULE D, PAGE 4, PART XI, LINE 2D LLS CANADA REVENUE 9,419,607 SCHEDULE D, PAGE 4, PART XII, LINE 2D LLS CANADA EXPENSES 10,044,313 SCHEDULE D, PAGE 4, PART XII, LINE 4B LLS CANADA FOREIGN CURRENCY ADJ -37,393 true NORTH AMERICA RESEARCH FUNDING RESEARCH GRANTS 2060000 EUROPE RESEARCH FUNDING RESEARCH GRANTS 1601053 EUROPE INVESTMENTS INVESTMENTS 1355670 EAST ASIA RESEARCH FUNDING RESEARCH GRANTS 2001132 CENTRAL AMERICA & CARIBBEAN INVESTMENTS INVESTMENTS 7474713 MIDDLE EAST & NORTH AFRICA RESEARCH FUNDING RESEARCH GRANTS 120000 14612568 14612568 NORTH AMERICA RESEARCH GRANT 60000 WIRE ACCRUAL EAST ASIA & PACIFIC RESEARCH GRANT 67000 WIRE ACCRUAL EUROPE RESEARCH GRANT 199924 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 500000 CHECK ACCRUAL EUROPE RESEARCH GRANT 200000 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 300000 WIRE ACCRUAL EUROPE THERAPY ACCELERATION 1000000 WIRE FMV EAST ASIA & PACIFIC RESEARCH GRANT 7970 WIRE ACCRUAL EAST ASIA & PACIFIC RESEARCH GRANT 199987 WIRE ACCRUAL EAST ASIA & PACIFIC RESEARCH GRANT 67000 WIRE ACCRUAL EAST ASIS & PACIFIC RESEARCH GRANT 200000 WIRE ACCRUAL NORTH AMERICA RESEARCH GRANT 1200000 CHECK ACCRUAL EUROPE RESEARCH GRANT 133333 WIRE ACCRUAL EAST ASIA & PACIFIC RESEARCH GRANT 1459176 WIRE ACCRUAL MIDDLE EAST RESEARCH GRANT 120000 WIRE ACCRUAL EUROPE RESEARCH GRANT 67795 WIRE ACCRUAL 16 true false true true false false SCHEDULE F, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. THE ACCOUNTING METHOD UTILIZED FOR GRANTS REPORTED ON PART II IS THE ACCRUAL METHOD AS CONSISTENT WITH BOOKS AND RECORDS. SCHEDULE F, PAGE 1, PART I, LINE 3 NORTH AMERICA 2,060,000 0 EUROPE 1,601,053 0 EUROPE 0 1,355,670 EAST ASIA 2,001,132 0 CENTRAL AMERICA & CARIBBEAN 0 7,474,713 MIDDLE EAST & NORTH AFRICA 120,000 0 X X X X X X true THOMPSON HABIB & DENISON 80 HAYDEN AVENUE SUITE 300 LEXINGTON MA 02421 DIRECT MAI false 636196 -636196 COINSTAR 1800 114TH AVENUE SE BELLEVUE WA 98004 COIN COLLE false 5608294 572664 5035630 THE HERITAGE COMPANY INC PO BOX 16325 LITTLE ROCK AR 722316325 DIRECT MAI false 196344 -196344 5608294 1405204 4203090 All States LAKE TAHOE BIKE 3774761 3371512 403249 188170 19958 57813 24108 359554 BLACK TIE 2894684 1993008 901676 6462 579404 327130 205975 26770 647 208160055 185749967 22410088 5506546 10920094 5216459 837460 3995763 214829500 191114487 23715013 5701178 11519456 5601402 1067543 4382087 28271666 -4556653 false false 231305 10135 79111 182898 true 0.39000 231305 10135 79111 182898 272144 -40839 CT DC IA KY MI NJ NY PA TX WI true false false false 0.25000 0.75000 GORDON MILLER JR 3 INTERNATIONAL DRIVE SUITE 200 RYE BROOK NY 10573 false SEE SCHEDULE G PART IV false SCHEDULE G, PAGE 2, PART III, LINE 9 PENNSYLVANIA, TEXAS, WISCONSIN SCHEDULE G, PART IV SCHEDULE G PART I, LINE 2B LLS USED MAIL AMERICA COMMUNICATIONS, THOMPSON, HABIB & DENSION, AND THE HERITAGE COMPANY FOR ITS NATIONAL COMMUNITY CAMPAIGN AND DIRECT MAIL PROGRAMS. THESE PROGRAMS GENERATED GROSS RECEIPTS OF 20,238,259 DURING FISCAL YEAR 2019. LLS USED COINSTAR FOR ITS COIN COLLECTION DURING THE FISCAL YEAR 2019. SCHEDULE G PART II - LINE 2 CONTRIBUTIONS REPRESENT THE CASH DONATIONS IN EXCESS OF THE FAIR MARKET VALUE OF BENEFITS PROVIDED TO THE DONOR. SCHEDULE G PART III - LINE 16 THE LEUKEMIA AND LYMPHOMA SOCIETY DOES NOT HAVE AN OVERALL MANAGER FOR GAMING ACTIVITIES. EACH GAMING EVENT IS MANAGED LOCALLY BY THE SPECIFIC CHAPTER STAFF. true ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BELFER 1108 BRONX NY 10461 472209056 3 419980 ACCRUAL RESEARCH GRANT ATRIUM HEALTH FOUNDATION 208 EAST BOULEVARD ATTN ELECTA MCP CHARLOTTE NC 28203 566060481 3 82500 ACCRUAL RESEARCH GRANT BAYLOR COLLEGE OF MEDICINE P O BOX 301207 DALLAS TX 753031207 741613878 3 2643270 ACCRUAL RESEARCH GRANT BECKMAN RESEARCH INSTITUTE OF THE C 1500 EAST DUARTE ROAD DUARTE CA 91010 953432210 3 2063238 ACCRUAL RESEARCH GRANT BOARD OF TRUSTEES OF THE LELAND STA PO BOX 44253 SAN FRANCISCO CA 941444253 941156365 3 1207000 ACCRUAL RESEARCH GRANT BOSTON CHILDREN'S HOSPITAL PO BOX 414413 BOSTON MA 022414413 042774441 3 487000 ACCRUAL RESEARCH GRANT BOSTON UNIVERSITY RESEARCH ACCOUNTI POBOX 28763 NEW YORK NY 100878763 042103547 3 600666 ACCRUAL RESEARCH GRANT BRIGHAM AND WOMENS HOSPITAL PO BOX 3149 BOSTON MA 022413149 042312909 3 610000 ACCRUAL RESEARCH GRANT BROAD INSTITUTE INC 7 CAMBRIDGE CENTER CAMBRIDGE MA 02142 263428781 3 60000 ACCRUAL RESEARCH GRANT CHILDREN'S RESEARCH INSTITUTE 801 ROEDER RD SUITE 500 SILVER SPRING MD 20910 521640403 3 400000 ACCRUAL RESEARCH GRANT CINCINNATI CHILDREN'S HOSPITAL MEDI 3333 BURNET AVENUE CINCINATTI OH 45229 310833936 3 177000 ACCRUAL RESEARCH GRANT CLEVELAND CLINIC FOUNDATION PO BOX 931531 CLEVELAND OH 44195 340714585 3 200000 ACCRUAL RESEARCH GRANT COLD SPRING HARBOR LABORATORY 1 BUNGTOWN ROAD PO BOX 100 COLD SPRING HARBOR NY 11724 112013303 3 110000 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE BP437 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 3 4091500 ACCRUAL RESEARCH GRANT DANA-FARBER CANCER INSTITUTE BP437 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 3 27775 FMV THERAPY ACCELERATION EMORY UNIVERSITY 1599 CLIFTON RD NE 4TH FL 1599-0 ATLANTA GA 311935084 582137993 3 200000 ACCRUAL RESEARCH GRANT FORTY SEVEN INC 1490 OBRIEN DRIVE SUITE A MENLO PARK CA 94025 474065674 250000 FMV THERAPY ACCELERATION FRED HUTCHINSON CANCER RESEARCH CEN 1100 FAIRVIEW AVENUE NORTH J6-300 SEATTLE WA 981091024 237156071 3 723178 ACCRUAL RESEARCH GRANT H LEE MOFFITT CANCER CENTER & RESE PO BOX 742801 ATLANTA GA 303742801 593238634 3 1999997 ACCRUAL RESEARCH GRANT HACKENSACK MERIDIAN HEALTH 40 PROSPECT AVENUE HACKENSACK NJ 07601 010649794 3 110000 ACCRUAL RESEARCH GRANT HARVARD MEDICAL SCHOOL PO BOX 415649 BOSTON MA 022415649 042103580 3 60000 ACCRUAL RESEARCH GRANT ICAHN SCHOOL OF MEDICINE AT MOUNT S ONE GUSTAVE L LEVY PLACE BOX 350 NEW YORK NY 10029 136171197 3 419999 ACCRUAL RESEARCH GRANT INDIANA UNIVERSITY 509 E 3RD STREET DETROIT MI 482780867 356018940 3 200000 ACCRUAL RESEARCH GRANT INTERNATIONAL WALDENSTROM'S MACROGL 6144 CLARK CENTER AVE SARASOTA FL 34238 541784426 3 125000 ACCRUAL RESEARCH GRANT JOAN & SANFORD I WEILL MEDICAL COL 575 LEXINGTON AVE 9TH FL NEW YORK NY 10022 131623978 3 1647000 ACCRUAL RESEARCH GRANT LA JOLLA INSTITUTE FOR ALLERGY AND 9420 ATHENA CIRCLE LA JOLLA CA 92037 330328688 3 60000 ACCRUAL RESEARCH GRANT MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 022414876 041564655 3 225000 ACCRUAL RESEARCH GRANT MASSACHUSETTS INSTITUTE OF TECHNOLO 77 MASSACHUSETTS AVE NE18-901 CAMBRIDGE MA 02139 042103594 3 200000 ACCRUAL RESEARCH GRANT MAYO CLINIC ROCHESTER PO BOX 860334 MINNEAPOLIS MN 554860334 416011702 3 400000 ACCRUAL RESEARCH GRANT MONTEFIORE MEDICAL CENTER 111 EAST 210TH STREET BRONX NY 10467 131740114 3 200000 ACCRUAL RESEARCH GRANT MYELOPROLIFERATIVE NEOPLASMS RESEAR 180 N MICHIGAN AVENUE SUITE 1870 CHICAGO IL 60601 364330967 3 200000 ACCRUAL RESEARCH GRANT NEMOURS ALFRED I DUPONT HOSPITAL F PO BOX 414876 WILMINGTON DE 19803 590634433 3 39060 ACCRUAL RESEARCH GRANT NEW YORK UNIVERSITY SCHOOL OF MEDIC PO BOX 415026 BOSTON MA 022414150 135562308 3 619758 ACCRUAL RESEARCH GRANT NORTHWESTERN UNIVERSITY 633 CLARK - ROOM G547 EVANSTON IL 60208 362167817 3 377000 ACCRUAL RESEARCH GRANT OREGON HEALTH & SCIENCE UNIVERSITY 3181 SW SAM JACKSON PARK ROAD MAIL PORTLAND OR 97239 237083114 3 325000 ACCRUAL RESEARCH GRANT PERELMAN SCHOOL OF MEDICINE AT THE 3451 WALNUT STREET FRANKLIN BLDG P- PHILADELPHIA PA 191046205 231352685 3 235000 ACCRUAL RESEARCH GRANT REGENTS OF THE UNIVERSITY OF MICHIG BOX 223131 PITTSBURGH PA 152512131 386006309 3 925094 ACCRUAL RESEARCH GRANT ROCKEFELLER UNIVERSITY 1230 YORK AVENUE BOX 82 NEW YORK NY 10021 131624158 3 266999 ACCRUAL RESEARCH GRANT SANFORD BURNHAM PREBYS MEDICAL DISC 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 510197108 3 60000 ACCRUAL RESEARCH GRANT SEATTLE CHILDREN'S HOSPITAL 4800 SAND POINT WAY NE SEATTLE WA 98105 911156519 3 125000 ACCRUAL RESEARCH GRANT SLOAN KETTERING INSTITUTE FOR CANCE PO BOX 026338 NEW YORK NY 10087 131924236 3 2506332 ACCRUAL RESEARCH GRANT ST JUDE CHILDREN'S RESEARCH HOSPIT PO BOX 1000 DEPT 949 MEMPHIS TN 381480949 620646012 3 376999 ACCRUAL RESEARCH GRANT SUTRO 310 UTAH AVENUE 150 SOUTH SAN FRANCISCO CA 94080 975000 FMV THERAPY ACCELERATION TEMPLE UNIVERSITY PO BOX 824242 PHILADELPHIA PA 191824242 231365971 3 200000 ACCRUAL RESEARCH GRANT THE BOARD OF REGENTS OF THE UNIVERS 21 N PARK ST SUITE 6401 MADISON WI 537151218 231365971 3 200000 ACCRUAL RESEARCH GRANT THE CHILDREN'S HOSPITAL OF PHILADEL LOCKBOX 1457 PO BOX 8500 PHILADELPHIA PA 191781457 396006492 3 533300 ACCRUAL RESEARCH GRANT THE JOHNS HOPKINS UNIVERSITY SCHOOL 12529 COLLECTIONS CENTER DRIVE CHIC CHICAGO IL 60693 231352166 3 300000 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 432101016 520595110 3 409224 ACCRUAL RESEARCH GRANT THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 432101016 520595110 3 157795 ACCRUAL BEAT AML MASTER TRIA THE REGENTS OF THE UNIVERSITY OF CA BOX 0897 1855 FOLSOM STREET SUITE LOS ANGELES CA 900744872 316025986 3 660000 ACCRUAL RESEARCH GRANT THE SCRIPPS RESEARCH INSTITUTE 10550 NORTH TORREY PINES ROAD TPC-7 LA JOLLA CA 92037 946036493 3 60000 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY PO BOX 29789 NEW YORK NY 100879789 330435954 3 200000 ACCRUAL RESEARCH GRANT THE TRUSTEES OF COLUMBIA UNIVERSITY PO BOX 29789 NEW YORK NY 100879789 135598093 3 774000 ACCRUAL RESEARCH GRANT THE TRUSTEES OF THE UNIVERSITY OF P 3451 WALNUT STREET FRANKLIN BLDG P- PHILADELPHIA PA 191046205 135598093 3 527000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF ALABAMA AT BIRMIN 1530 3RD AVENUE SOUTH SUITE 1170 BIRMINGHAM AL 352940111 231352685 3 327000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF CHICAGO 5841 S MARYLAND AVE MC6092 CHICAGO IL 60637 636005396 3 227000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF IOWA DIVISION OF SPONSORED PROGRAMS GILM IOWA CITY IA 52242 362177139 3 200000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF NORTH CAROLINA AT PO BOX 402420 ATLANTA GA 303842420 426004813 3 795688 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS MD ANDERSON PO BOX 4266 HOUSTON TX 772104266 566001393 3 1969924 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF TEXAS SOUTHWESTER PO BOX 841753 DALLAS TX 752841753 746001118 3 110000 ACCRUAL RESEARCH GRANT THE UNIVERSITY OF UTAH 201 S PRESIDENTS CIRCLE RM 145 SALT LAKE CITY UT 841129003 756002868 3 110000 ACCRUAL RESEARCH GRANT THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 876000525 3 60000 ACCRUAL RESEARCH GRANT TUFTS MEDICAL CENTER 800 WASHINGTON STREET 453 BOSTON MA 02111 236434390 3 52500 ACCRUAL RESEARCH GRANT UNIVERSITY OF ARKANSAS FOR MEDICAL 4301 W MARKHAM SLOT 545 LITTLE ROCK AR 72205 042103634 3 199990 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA IRVINE 141 INNOVATION DRIVE SUITE 250 IR IRVINE CA 926977600 716056774 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF CALIFORNIA SAN FRANC BOX 0897 1855 FOLSOM STREET SUITE LOS ANGELES CA 900744872 952540117 3 60000 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO DENVER ANSC PO BOX 910238 DENVER CO 80291-0238 AURORA CO 80045 946036493 3 1192000 ACCRUAL RESEARCH GRANT UNIVERSITY OF COLORADO-DENVER 12700 E 19TH AVENUE AURORA CO 80045 846000555 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF FLORIDA 33 TIGERT HALL P O BOX 113001 GAINESVILLE FL 326113001 846000555 3 325387 ACCRUAL RESEARCH GRANT UNIVERSITY OF KENTUCKY 500 SOUTH LIMESTONE LEXINGTON KY 405060001 596002052 3 59993 ACCRUAL RESEARCH GRANT UNIVERSITY OF MARYLAND BALTIMORE PO BOX 41428 BALTIMORE MD 212036428 616033693 3 300000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MASSACHUSETTS MEDICAL 55 LAKE AVENUE NORTH WORCESTER MA 016550002 526002033 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MIAMI PO BOX 405803 ATLANTA GA 303845803 043167352 3 1270000 ACCRUAL RESEARCH GRANT UNIVERSITY OF MINNESOTA TWIN CITIE 450 MCNAMARA ALUMNI CENTER MINNEAPOLIS MN 55414 590624458 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF NOTRE DAME 511 MAIN BUILDING NOTRE DAME IN 46556 416007513 3 200000 ACCRUAL RESEARCH GRANT UNIVERSITY OF SOUTHERN CALIFORNIA 1425 SAN PABLO ST LOS ANGELES CA LOS ANGELES CA 90089 350868188 3 55000 ACCRUAL RESEARCH GRANT UNIVERSITY OF VIRGINIA PO BOX 400195 CHARLOTTESVILLE VA 229044195 951642394 3 110000 ACCRUAL RESEARCH GRANT UNIVERSITY OF WISCONSIN AT MADISON 201 BASCOM HALL MADISON WI 53706 237173411 3 67000 ACCRUAL RESEARCH GRANT VAN ANDEL RESEARCH INSTITUTE 333 BOSTWICK AVE NE GRAND RAPIDS MI 49503 396006492 3 110000 ACCRUAL RESEARCH GRANT VANDERBILT UNIVERSITY MEDICAL CENTE DEPT 1236 PO BOX 121236 DALLAS TX 75312 522000820 3 282122 ACCRUAL RESEARCH GRANT VERASTEM 117 KENDRICK STREET SUITE 500 NEEDHAM HEIGHTS MA 02494 620476822 500000 FMV THERAPY ACCELERATION WASHINGTON UNIVERSITY IN ST LOUIS 1 BROOKINGS DR ST LOUIS MO 63112 273269467 3 220000 ACCRUAL RESEARCH GRANT WASHINGTON UNIVERSITY SCHOOL OF MED 700 ROSEDALE AVENUE CAMPUS BOX 1034 ST LOUIS MO 631121408 430653611 3 352346 ACCRUAL RESEARCH GRANT YALE UNIVERSITY PO BOX 208327 NEW HAVEN CT 065201873 430653611 3 322500 ACCRUAL RESEARCH GRANT 80 3 COPAY ASSISTANCE CLL 5325 16044725 COPAY ASSISTANCE LYMPHOMA 2450 4490619 COPAY ASSISTANCE MDS 2989 8096099 COPAY ASSISTANCE MYELOMA 12246 57109928 COPAY ASSISTANCE MANTEL 1421 3388994 COPAY ASSISTANCE WALDENST 147 213828 COPAY ASSISTANCE ALL 147 153615 COPAY ASSISTANCE AML 2309 7664136 COPAY ASSISTANCE CML PATIENT TRAVEL ASSISTANC 3354 1728001 PATIENT AID 15656 2499615 SCHEDULE I, PAGE 1, PART I, LINE 2 FIDUCIARY RESPONSIBILITY AND TRANSPARENCY TO OUR DONORS IS A HIGH PRIORITY. THE LEUKEMIA & LYMPHOMA SOCIETY (LLS) PLACES CONSIDERABLE EMPHASIS ON THE OVERSIGHT OF GRANT SPENDING. TO ACCOMPLISH THIS WE REQUIRE THE SUBMISSION OF ANNUAL FINANCIAL REPORTS FOR EACH OF OUR ACTIVE GRANTS. THE REPORT MUST BE SIGNED BY THE FINANCIAL OFFICER AND/OR THE DESIGNATED OFFICIAL OF THE INSTITUTION HOSTING THE AWARD. AT THE END OF THE GRANT, WE REQUIRE A FINAL FINANCIAL REPORT THAT PROVIDES AN OVERVIEW OF ALL SPENDING THROUGH THE DURATION OF THE AWARD. WE REQUIRE SPECIFIC ACCOUNTING OF SPENDING ON PERSONNEL, CONSULTANTS, EQUIPMENT PURCHASES, SUPPLIES, TRAVEL, PATIENT CARE COSTS, ANIMAL CARE COSTS, AND ANY OTHER EXPENSE A GRANTEE MAY INCUR. WE HAVE SPECIFIC INSTRUCTIONS AND DOLLAR AMOUNT LIMITATIONS SET FOR MANY OF THESE CATEGORIES DEPENDING ON THE AWARD TYPE. FINANCIAL REPORTS ARE REVIEWED FOR NUMERICAL ACCURACY, ADHERENCE TO OUR GUIDELINES, AND FOR THE VERIFICATION OF APPROVAL FROM THE INSTITUTION'S FINANCIAL OFFICER. IF THE GRANTEE DOES NOT SUBMIT AN ANNUAL FINANCIAL REPORT BY THE DUE DATE OUTLINED IN THEIR CONTRACT, FUNDING IS SUSPENDED UNTIL LLS RECEIVES AND APPROVES THE DELINQUENT REPORT. PATIENT FINANCIAL AID: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR MANY EXPENSES RELATED TO THEIR TREATMENT. SOMETIMES PATIENTS HAVE TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE TREATMENT EXPENSES. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS HAS ESTABLISHED A PATIENT FINANCIAL AID PROGRAM THAT PROVIDES APPLICANTS, WHO RESIDE IN THE US AND HAVE A BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. CO-PAY ASSISTANCE: PATIENT APPLICATIONS ARE PROCESSED ON A FIRST COME, FIRST SERVED BASIS. ELIGIBLE PATIENTS MUST RESIDE IN THE UNITED STATES OR PUERTO RICO, HAVE A PROGRAM COVERED BLOOD CANCER DIAGNOSIS CONFIRMED BY A PHYSICIAN, MAINTAIN MEDICAL/PRESCRIPTION INSURANCE AND HAVE HOUSEHOLD INCOME AT OR BELOW 500% OF THE US FEDERAL POVERTY LEVEL AS ADJUSTED BY HOUSEHOLD SIZE AND COST OF LIVING INDEX. PATIENTS MUST PROVIDE PROOF OF INSURANCE AND INCOME. QUALIFYING PATIENTS ARE APPROVED FOR A TWELVE MONTH COVERAGE PERIOD. PATIENT TRAVEL ASSISTANCE: THE LEUKEMIA AND LYMPHOMA SOCIETY (LLS) REGULARLY RECEIVES CALLS FROM PATIENTS WHO CANNOT MOVE FORWARD WITH THEIR POTENTIALLY LIFE-SAVING TREATMENTS BECAUSE THEY CANNOT AFFORD TO PAY FOR TRANSPORTATION TO GET TO THEIR PROVIDERS, E.G. DOCTORS, HOSPITALS, TRANSPLANT CENTERS, AND RESEARCH OR CLINICAL TRIAL CENTERS. SOMETIMES PATIENTS HAVE TO TRAVEL OUT-OF-STATE TO GET THEIR PRESCRIBED AND RECOMMENDED TREATMENTS, OFTENTIMES RESULTING IN PATIENTS HAVING TO CHOOSE BETWEEN BASIC NEEDS SUCH AS FOOD OR SHELTER AND THEIR HEALTH CARE. IN AN EFFORT TO ALLEVIATE SUCH HARDSHIPS, LLS ESTABLISHED THE TRAVEL ASSISTANCE PROGRAM WHICH PROVIDES APPLICANTS, WHO ARE US CITIZENS OR PERMANENT RESIDENTS, HAVE AN ANNUAL INCOME AT OR BELOW 500% OF THE FEDERAL POVERTY LEVEL (FPL) AND HAVE A CONFIRMED BLOOD CANCER DIAGNOSIS, A ONE-TIME ANNUAL STIPEND TO HELP DEFER SOME OF THESE EXPENSES. LLS ROUTINELY CONDUCTS AN OPERATIONAL AUDIT VERIFYING APPLICANTS ARE IN COMPLIANCE WITH PROGRAM GUIDELINES AND PROGRAM CRITERIA. X X X X X true false false false false false false true false LOUIS J DEGENNARO PRESIDENT & CEO 630962 119500 31454 17325 24361 823602 ROSEMARIE A LOFFREDO - END 33119 EVP CHIEF FIN OFFICE 334029 47450 23753 9771 12927 427930 GORDON MILLER JR EVP CHIEF FIN OFFICE 252597 30338 824 13750 25923 323432 ROBERT BECK - END 7519 EVP CHIEF OPER OFFIC 211585 25000 20145 835 257565 GWEN NICHOLS EVP CHIEF MED OFFICE 386438 70441 24622 6055 32331 519887 ALICE O'ROURKE - END 81518 EVP CHIEF DEV OFFICE 175641 212033 7710 23767 419151 KATHY GRIESENBECK EVP CHIEF REL OFFICE 315071 40386 22329 13750 22945 414481 LEE M GREENBERGER SVP CHIEF SCIEN OFFI 277118 56199 11391 10307 32974 387989 THOMAS OSGOOD EVP CHIEF HUMAN RESO 267909 37212 7004 5201 19606 336932 MARCIE KLEIN EVP COMMUNICATIONS 254475 34077 3697 13750 21449 327448 ANDREW S COCCARI - END 7618 EVP CHIEF PROD OFFIC 190403 942 6697 19926 217968 SCHEDULE J, PAGE 1, PART I, LINE 4 ALICE O'ROURKE - END 8/15/18 208,984 0 0 SCHEDULE J, PAGE 1, PART I, LINE 7 SEVERANCE PAYMENTS RECEIVED ARE INCLUDED IN THE RESPECTIVE INDIVIDUAL'S TAXABLE INCOME AND REPORTED ON SCHEDULE J, PART II, COLUMN B (III). BONUSES WERE PAID BASED ON THE ACHIEVEMENT OF THE EMPLOYEE INDIVIDUAL PERFORMANCE. BONUSES WERE CAPPED ACCORDING TO LLS'S POLICY. THESE AMOUNTS ARE REPORTED ON SCHEDULE J PART II, COLUMN (B)(II). X 173 1177354 FAIR MARKET VALUE X 114 X PRINTED ITEMS 20 X VARIOUS 175 1615633 false true false SCHEDULE M, PAGE 2, PART II PART I, COLUMN (B) LLS IS REPORTING THE NUMBER OF CONTRIBUTIONS FOR EACH OF THE ITEMS IN PART I, NOT THE NUMBER OF INDIVIDUAL ITEMS. PART I, LINE 33 - EXPLANATION FOR NOT REPORTING REVENUE LLS ONLY RECORDS DONATED SECURITIES AS REVENUE. ALL OTHER ITEMS FOR WHICH COLUMN A IS CHECKED ARE NOT RECORDED AS REVENUE OR EXPENSE BECAUSE THEY WOULD NOT HAVE BEEN PURCHASED HAD THEY NOT BEEN DONATED, AND ARE IMMATERIAL IN AMOUNT RELATIVE TO THE STATEMENTS OF LLS. FORM 990, PAGE 2, PART III, LINE 4A A) RESEARCH PROGRAMS: WE WILL CONTINUE TO SUPPORT RESEARCH THROUGH OUR INNOVATIVE AND INTEGRATED FUNDING PROGRAMS, UNTIL EVERY PATIENT HAS A SAFE AND EFFECTIVE THERAPY. IN FISCAL YEAR 2019, LLS SUPPORTED RESEARCH IN THE U.S., CANADA AND 7 OTHER COUNTRIES WITH A TOTAL RESEARCH DISBURSEMENT OF APPROXIMATELY 44.3 MILLION. RESEARCH FUNDING WAS DISTRIBUTED ACROSS ALL BLOOD CANCERS. BEAT AML MASTER TRIAL THE BEAT AML MASTER TRIAL, A COLLABORATIVE CLINICAL TRIAL TESTING SEVERAL NOVEL TARGETED THERAPIES FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA(AML) DESIGNED TO FACILITATE FDA APPROVAL OF NEW DRUGS AND CHANGE THE TREATMENT PARADIGM FOR PATIENTS DIAGNOSED WITH AML BY DEVELOPING MORE INDIVIDUALIZED, EFFECTIVE TREATMENT APPROACHES. THE MASTER TRIAL INVOLVES COLLABORATIONS WITH MULTIPLE MEDICAL INSTITUTIONS, DRUG COMPANIES, A GENOMIC PROVIDER, A CLINICAL RESEARCH ORGANIZATION, AND THE FDA, ALL OF WHOM HAVE COMMITTED TO WORKING COLLABORATIVELY. MORE THAN 760 PATIENTS HAVE BEEN SCREENED IN 11 STUDY ARMS AT 16 CANCER CENTERS ACROSS THE COUNTRY. OUR CRITICAL ROLE LLS PROGRAMS ACCELERATE RELEVANT RESEARCH OUTCOMES BY: - BUILDING A FOCUSED RESEARCH WORK-FORCE: ASSURING THE NEXT ROUND OF BREAKTHROUGHS REQUIRES THAT YOUNG INVESTIGATORS BE ENCOURAGED TO WORK IN BLOOD CANCER RESEARCH FIELDS. - TURNING DISCOVERIES INTO NEW THERAPIES: FUNDAMENTAL NEW FINDINGS CAN BE TRANSLATED INTO SAFE AND EFFECTIVE TREATMENTS THAT CAN ULTIMATELY PROLONG AND ENHANCE PATIENT LIVES. - SUPPORTING SYNERGY: LARGE GRANTS AND CONTRACTS ENABLE SCIENTISTS IN ACADEMIA AND THE PRIVATE-SECTOR TO COLLABORATE, COMBINING RESOURCES AND EXPERTISE TO PRODUCE MORE AND FASTER ADVANCES. - FILLING A VOID: RESEARCH PROJECTS THAT ARE HIGH-RISK AND/OR ADDRESS RARE CANCERS ARE LESS LIKELY TO BE FUNDED BY GOVERNMENT AGENCIES OR FOR-PROFIT COMPANIES, BUT MAY PROVIDE IMPORTANT ADVANCES. - SPEEDING NEW TREATMENTS TO PATIENTS: PARTNERING WITH BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES CAN ADVANCE PROMISING THERAPIES THROUGH CLINICAL TESTING, FASTER. PAST ADVANCES MADE WITH LLS RESEARCH FUNDING GENEROUS DONORS HAVE HELPED LLS SUPPORT RESEARCH THAT HAS ALREADY BENEFITED BLOOD CANCER PATIENTS AND MANY OTHERS. ADVANCES INCLUDE: - MULTI-DRUG THERAPIES THAT ARE MORE EFFECTIVE THAN TREATMENTS WITH SINGLE ANTI-CANCER AGENTS, - BONE MARROW / STEM CELL TRANSPLANTATION AND SUPPORTIVE CARE TREATMENTS FOR PATIENTS WHO RELAPSE DESPITE THE BEST AVAILABLE THERAPY, AND, - TESTS THAT DISTINGUISH SPECIFIC CHARACTERISTICS OF PARTICULAR BLOOD CANCERS FOR ACCURATE DIAGNOSIS OF CANCER SUBTYPES, AND FOR "RISK STRATIFICATION" TO SELECT AN OPTIMAL THERAPY. TARGETED THERAPY RESEARCH DISCOVERING THE MOLECULAR ABNORMALITIES THAT CAUSE PARTICULAR TYPES OF BLOOD CANCER HAS BEEN USEFUL IN DIAGNOSIS AND RISK STRATIFICATION, AND IN NEW "TARGETED DRUG" DEVELOPMENT. LLS-FUNDED INVESTIGATORS HAVE HELPED ADVANCE MOLECULARLY TARGETED TREATMENTS THAT CAN SELECTIVELY KILL BLOOD CANCER CELLS VERSUS NORMAL CELLS. MANY OF THESE NEW TREATMENTS BENEFIT NOT ONLY BLOOD CANCER PATIENTS, BUT ALSO PATIENTS WITH OTHER DISEASES. FOR EXAMPLE: - GLEEVEC IS FDA-APPROVED FOR PATIENTS OF ALL AGES WITH CHRONIC MYELOID LEUKEMIA (CML), AND IS ALSO APPROVED FOR PATIENTS WITH ONE FORM OF ACUTE LYMPHOID LEUKEMIA (ALL), MYELODYSPLASTIC SYNDROMES (MDS), MYELOPROLIFERATIVE DISORDERS AND RARE FORMS OF STOMACH AND SKIN CANCERS. RELATED DRUGS, SPRYCEL AND TASIGNA, ARE APPROVED FOR PATIENTS WHO DO NOT BENEFIT FROM GLEEVEC. ONE OR MORE OF THESE DRUGS ARE ALSO SHOWING PROMISE FOR PATIENTS WITH VARIOUS LYMPHOMAS, ACUTE MYELOID LEUKEMIA (AML), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), AND OTHER CANCERS, INCLUDING BRAIN, BREAST, HEAD-AND-NECK, LUNG, PANCREATIC, AND PROSTATE CANCERS, AND PATIENTS WITH OTHER DISEASES INCLUDING ALZHEIMER'S, ASTHMA AND PULMONARY HYPERTENSION. - RITUXAN WAS THE FIRST FDA-APPROVED, ANTI-CANCER ANTIBODY DRUG, DEVELOPED FOR PATIENTS WITH FORMS OF B-CELL NON-HODGKIN LYMPHOMA (NHL). IT IS NOW ALSO APPROVED FOR CLL PATIENTS AND AS A "MAINTENANCE" THERAPY FOR FOLLICULAR LYMPHOMA PATIENTS, AND SHOWING PROMISE FOR PATIENTS WITH ALL AND AFTER STEM CELL TRANSPLANTATION. IN ADDITION, IT IS APPROVED FOR TREATING PATIENTS WITH SEVERE RHEUMATOID ARTHRITIS AND TWO OTHER TYPES OF AUTOIMMUNE DISEASES. A RELATED ANTIBODY DRUG, ARZERRA, IS APPROVED FOR CLL PATIENTS AND SHOWING WIDER PROMISE. - VELCADE, THALIDOMID AND REVLIMID ARE FDA-APPROVED FOR PATIENTS WITH MYELOMA AND ARE ALSO HELPING SOME PATIENTS WITH HODGKIN LYMPHOMA AND NHL. KRYPOLIS WAS RECENTLY APPROVED FOR MYELOMA PATIENTS FOR WHOM AT LEAST TWO PRIOR THERAPIES WERE INSUFFICIENT. ONE OR MORE OF THESE DRUGS ARE NOW BEING TESTED FOR PATIENTS WITH T-CELL AND B-CELL FORMS OF LYMPHOMA, ACUTE LEUKEMIAS, AS WELL AS AIDS-RELATED KAPOSI SARCOMA AND BRAIN, BREAST, COLORECTAL, HEAD-AND-NECK, KIDNEY, LIVER, LUNG, OVARIAN AND PROSTATE CANCERS, AND ALZHEIMER'S DISEASE. - ISTODAX, ZOLINZA, DACOGEN AND VIDAZA TARGET SMALL CHEMICAL, "EPIGENETIC" CHANGES. THE FIRST TWO DRUGS ARE APPROVED FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAS; THE LATTER DRUGS ARE APPROVED FOR MDS PATIENTS. ONE OR MORE OF THESE DRUGS ARE BEING TESTED FOR PATIENTS WITH ALL, AML, CML, CLL, MYELOMA AND FORMS OF NHL, AFTER STEM CELL TRANSPLANTATION, AND FOR PATIENTS WITH BREAST, BRAIN, KIDNEY, COLORECTAL, HEAD-AND-NECK, LUNG, STOMACH, PROSTATE AND OVARIAN CANCERS, MELANOMA AS WELL AS SICKLE CELL DISEASE AND PERSISTENT HIV INFECTIONS. - ADCETRIS WAS APPROVED IN 2011, AND IN JANUARY 2012. IT IS AN ANTIBODY- DRUG CONJUGATE THAT COMBINES AN ANTI-CD30 ANTIBODY AND THE CYTOTOXIC DRUG MONOMETHYL AURISTATIN E (MMAE). IT IS AN ANTI-NEOPLASTIC AGENT USED IN THE TREATMENT OF HODGKIN LYMPHOMA AFTER FAILURE OF AUTOLOGOUS STEM CELL TRANSPLANT OR THOSE WHO ARE NOT ELIGIBLE FOR ASCT AFTER FAILURE OF AT LEAST 2 MUTIAGEN CHEMOTHERAPY REGIMENS. ADCETRIS WAS ALSO APPROVED FOR SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA WITH FAILURE OF AT LEAST ONE PRIOR TREATMENT. - GAZYVA IS A HUMANIZED MONOCLONAL ANTIBODY USED AS A COMBINATION TREATMENT WITH CHLORAMBUCIL TO TREAT PATIENTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA. IT WAS APPROVED BY THE FDA IN NOVEMBER 2013 AND BY THE EHA IN JULY 2014. - IMBRUVICA IS AN ORAL SMALL MOLECULE INHIBITOR AGAINST BTK KINASE. IT WAS FIRST APPROVED BY THE US FDA ON NOVEMBER 13, 2013 FOR THE TREATMENT OF MANTLE CELL LYMPHOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ON FEB. 12, 2014 THE US FDA EXPANDED THE APPROVED USE OF THE DRUG TO CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR TREATMENT. ADDITIONALLY, IT RECEIVED FURTHER EXPANSION TO TREAT 17P DELETION IN CLL WITH OR WITHOUT PRIOR THERAPY. - ZYDELIG IS AN ORAL SMALL MOLECULE INHIBITOR THAT BLOCKS THE DELTA ISOFORM OF THE ENZYME PHOSPHOINOSITIDE 3-KINASE. IT WAS APPROVED BY THE FDA IN JULY 2014 TO TREAT RELAPSED/REFRACTORY CLL IN COMBINATION WITH RITUXAN. IT WAS ALSO APPROVED TO USE AS A MONOTHERAPY FOR RELAPSED MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA. OTHER ACTIVE RESEARCH DIRECTIONS LLS-FUNDED RESEARCHERS ARE ALSO EXPLORING OTHER AREAS OF RESEARCH THAT HOLD PROMISE FOR PATIENTS: - NOVEL STEM CELL TRANSPLANTATION PROCEDURES: THESE INCLUDE SO-CALLED "MINI" TRANSPLANTS THAT USE LESS TOXIC PRE-TRANSPLANT TREATMENTS AND ENGINEERED DONOR CELLS THAT HELP REDUCE POST-TRANSPLANT COMPLICATIONS, MAKING THESE POTENTIALLY CURATIVE TREATMENTS AVAILABLE TO MORE PATIENTS. - IMMUNOTHERAPIES: INCLUDING ANTIBODIES, VACCINES AND ENGINEERED IMMUNE CELLS, THESE TARGETED THERAPIES HELP A PATIENT'S IMMUNE SYSTEM FIGHT INFECTIONS AND KILL RESIDUAL CANCER CELLS, PROLONGING REMISSIONS, AND PERHAPS ONE DAY REPLACING TOXIC CHEMOTHERAPIES. - DIAGNOSTICS: NEW TECHNOLOGIES MAKE IT POSSIBLE TO CHARACTERIZE THE ABNORMALITIES IN INDIVIDUAL CANCER CASES IN MOLECULAR DETAIL. THIS INFORMATION CAN BE USED TO HELP CHOOSE THE BEST POSSIBLE TREATMENT FOR EACH PATIENT, ESPECIALLY AS MORE TARGETED THERAPIES BECOME AVAILABLE. - QUALITY OF LIFE RESEARCH: THESE STUDIES INCREASE OUR UNDERSTANDING OF HOW SPECIFIC TREATMENTS CAN CAUSE DEBILITATING SIDE-EFFECTS, INCLUDING LATE-EFFECTS, AND WHICH PATIENTS ARE AT RISK FOR DEVELOPING THESE COMPLICATIONS, SO THAT THEY CAN BE BETTER MANAGED OR EVEN PREVENTED. DRIVING RESEARCH TO ADDRESS UNMET MEDICAL NEEDS LLS CONTINUES TO SOLICIT AND SUPPORT RESEARCH FOCUSED ON IMPROVING BLOOD CANCER PATIENTS' QUALITY OF LIFE AFTER TODAY'S CURATIVE THERAPIES. ALSO IN 2019, FOR THE EIGHTH YEAR, LLS ACTIVELY RECRUITED RESEARCH PROPOSALS IN SIX OTHER UNDERDEVELOPED RESEARCH AREAS IN WHICH PROGRESS IS LIKELY TO IMPROVE OUTCOMES FOR PATIENTS WITH PARTICULARLY URGENT NEEDS. NEW RESEARCH IS FOCUSED ON: - DEVELOPMENT OF NOVEL THERAPEUTIC STRATEGIES FOR PATIENTS WITH NON- CUTANEOUS T-CELL LYMPHOPROLIFERATIVE DISORDERS - DEVELOP NOVEL TARGETED THERAPIES FOR CLL PATIENTS, WITH REAL CURATIVE POTENTIAL - DEVELOP NOVEL TREATMENT STRATEGIES FOR MDS AND AML PATIENTS - DEVELOP NOVEL TARGETED THERAPIES FOR PATIENTS WITH HIGH-RISK MYELOMA - DEVELOPMENT OF NEW-TARGETED THERAPIES FOR INDOL FORM 990, PAGE 2, PART III, LINE 4B B) PATIENT & COMMUNITY SERVICES: PUBLICATIONS AND THE LLS WEBSITE. SUPPORT SERVICES ARE PROVIDED BY PROFESSIONALS OR RIGOROUSLY TRAINED PEER VOLUNTEERS. ALL RESOURCES ARE PROVIDED THROUGH A VARIETY OF MEDIA - PRINT, ONLINE, BY PHONE, AND FACE- TO-FACE IN COMMUNITIES. A NUMBER OF RESOURCES ARE AVAILABLE IN SPANISH FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. PRINT PUBLICATIONS: AN EXTENSIVE CATALOG OF EDUCATION MATERIALS IS OFFERED FREE-OF-CHARGE TO PATIENTS AND HEALTHCARE PROFESSIONALS. EACH YEAR, LLS DISTRIBUTES DISEASE AND SUPPORT BOOKLETS AND FACT SHEETS THROUGH THE INFORMATION RESOURCE CENTER, LLS WEBSITE AND LLS CHAPTERS. EACH YEAR, LLS PUBLISHES AN ANNUAL COMPILATION OF DATA AVAILABLE FOR BLOOD CANCERS, INCLUDING THE ESTIMATED NUMBERS OF NEW BLOOD CANCER CASES AND DEATHS, THE MOST RECENT STATISTICS AVAILABLE FOR INCIDENCE, MORTALITY AND SURVIVAL. IN 2019, 717,119 FREE PRINTED DISEASE AND SUPPORT BOOKLETS AND 8,621 FACT SHEETS WERE ORDERED. ADDITIONALLY, THERE WERE 129,388 PAGE VIEWS OF THESE BOOKLETS AND FACT SHEETS ON THE LLS WEBSITE. EDUCATION MATERIALS ARE AVAILABLE TO DOWNLOAD OR ORDER AT WWW.LLS.ORG/BOOKLETS. MANY MATERIALS ARE AVAILABLE IN ENGLISH, SPANISH AND FRENCH, AND SELECT MATERIALS ARE AVAILABLE IN ADDITIONAL LANGUAGES. FINANCIAL ASSISTANCE IN 2019, A COMBINED 100,656,064 WAS DISBURSED TO PATIENTS THROUGH THE CO- PAY ASSISTANCE PROGRAM (97,150,904), THE LLS SUSAN LANG PATIENT TRAVEL ASSISTANCE PROGRAM (1,005,560), THE LLS URGENT NEED PROGRAM (1,168,000), AND THE LLS PATIENT AID PROGRAM (1,331,600). CO-PAY ASSISTANCE PROGRAM THE CO-PAY ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS MEET THEIR HEALTH INSURANCE OR MEDICARE PLAN PART B OR D PREMIUMS OR CO- PAYMENT OBLIGATIONS RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. PATIENTS WITH PRESCRIPTION DRUG COVERAGE, MEDICARE BENEFICIARIES UNDER MEDICARE PART B AND/OR MEDICARE PART D, MEDICARE SUPPLEMENTARY HEALTH INSURANCE OR MEDICARE ADVANTAGE SHOULD CHECK WITH LLS TO SEE IF THEY MEET ELIGIBILITY REQUIREMENTS TO RECEIVE FINANCIAL SUPPORT. CO-PAY ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY BY SPECIFIC BLOOD CANCER DIAGNOSIS. IN 2019, 97,150,904 WAS PROVIDED TO 27,034 PATIENTS THROUGH THE LLS CO-PAY ASSISTANCE PROGRAM. SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM THE SUSAN LANG PAY-IT-FORWARD PATIENT TRAVEL ASSISTANCE PROGRAM SUPPORTS QUALIFYING BLOOD CANCER PATIENTS WITH TRAVEL AND LODGING EXPENSES RELATED TO TREATING THEIR BLOOD CANCER DIAGNOSIS. TRAVEL ASSISTANCE IS SUBJECT TO FUNDING AVAILABILITY. IN 2019, 1,105,560 WAS PROVIDED TO 2202 PATIENTS THROUGH THE LLS SUSAN LANG TRAVEL PROGRAM. URGENT NEED PROGRAM THE URGENT NEED PROGRAM WAS ESTABLISHED TO HELP PEDIATRIC AND YOUNG ADULT BLOOD CANCER PATIENTS, OR ADULT BLOOD CANCER PATIENTS ENROLLED IN CLINICAL TRIALS, WHO ARE IN ACUTE FINANCIAL NEED. THE PROGRAM PROVIDES ELIGIBLE PATIENTS ASSISTANCE FOR NON-MEDICAL EXPENSES INCLUDING RENT, MORTGAGE, LODGING, UTILITIES, CHILDCARE, ELDER CARE, FOOD, TRANSPORTATION, CAR REPAIR, CAR INSURANCE, PHONE SERVICE, AND ACUTE DENTAL WORK RELATED TO TREATMENT. IN 2019, 1,168,000 WAS PROVIDED TO 2,357 PATIENTS THROUGH THE LLS URGENT NEED PROGRAM. PATIENT AID PROGRAM THE PATIENT AID PROGRAM PROVIDES FINANCIAL ASSISTANCE TO BLOOD CANCER PATIENTS. ELIGIBLE PATIENTS WILL RECEIVE A ONE-TIME 100 STIPEND TO HELP OFFSET EXPENSES. IN 2019, 1,331,600 WAS PROVIDED TO 13,316 PATIENTS THROUGH THE LLS PATIENT AID PROGRAM. COMMUNITY PROGRAMS SERVICES ARE PROVIDED IN COMMUNITIES TO PATIENTS AND THEIR FAMILIES, CAREGIVERS AND HEALTHCARE PROFESSIONALS BY PATIENT ACCESS STAFF AND TRAINED VOLUNTEERS WHO HAVE SPECIFIC SUPPORT AND OUTREACH ROLES. STAFF ARE HEALTHCARE AND ALLIED HEALTHCARE PROFESSIONALS, OFTEN WITH A BACKGROUND IN ONCOLOGY NURSING, PUBLIC HEALTH OR SOCIAL WORK; VOLUNTEERS ARE TYPICALLY PATIENTS OR CAREGIVERS WHO UNDERGO RIGOROUS BACKGROUND CHECKS AND TRAINING. STAFF AND VOLUNTEERS SERVE AS LIAISONS WITH COMMUNITY AND REGIONAL ONCOLOGY/HEMATOLOGY HEALTHCARE PROFESSIONALS AND TREATMENT CENTERS, AND PROVIDE COMMUNITY-BASED OUTREACH, EDUCATION, AND SUPPORT IN A VARIETY OF FORMS. REGIONAL BLOOD CANCER CONFERENCES: LLS WORKS TO ELEVATE OUR VISIBILITY IN COMMUNITIES WE SERVE BY HOSTING LARGER-SCALE CONFERENCES, GEARED FOR PATIENTS, CAREGIVERS AND HEALTHCARE PROFESSIONALS. THESE EVENTS ARE A CATALYST FOR BRINGING MANY DEDICATED PEOPLE TOGETHER TO FOCUS ON BLOOD CANCER AWARENESS, INFORMATION AND THE LATEST ADVANCES IN MEDICAL SCIENCE. THEY ARE DESIGNED FOR PATIENTS AND CAREGIVERS BUT ARE ATTENDED BY SOME LOCAL HEALTHCARE PROFESSIONALS (NURSES AND SOCIAL WORKERS) AS WELL. IN 2019, 10 BCC CONFERENCES WERE HELD WITH 3,693 ATTENDEES. LLS COMMUNITY THE ONLINE "LLS COMMUNITY" WAS LAUNCHED ON FEBRUARY 1, 2016 TO HONOR THE MEMORY OF MICHAEL GARIL, WHO WAS DIAGNOSED WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN 1974 AT THE AGE OF SEVEN. IT WAS DESIGNED TO PROVIDE A WAY FOR PATIENTS AND CAREGIVERS TO: 1) BECOME PART OF A SOCIAL NETWORK TO CONNECT WITH PATIENTS AND CAREGIVERS IN SIMILAR SITUATIONS AND BECOME EMPOWERED; 2) PROVIDE INFORMATION ABOUT ONESELF AND ONE'S DISEASE, TO BECOME PART OF THE RESEARCH TO CURE BLOOD CANCERS; AND 3) GAIN THE LATEST INFORMATION ABOUT ONE'S DISEASE, LEARN ABOUT SURVIVORSHIP ISSUES, AND ABOUT CLINICAL TRIALS. BY THE END OF FY 2019, THERE WERE APPROXIMATELY 12,000 COMMUNITY MEMBERS AND 93,212 RESPONSES TO THE "QUESTIONS OF THE DAY," AS WELL AS CLOSE TO 62,050 COMMENTS POSTED BY USERS. FAMILY SUPPORT GROUPS: THROUGHOUT THE US, IN 2019 LLS SUPPORTED OR HOSTED 127 FAMILY SUPPORT GROUPS FOR PATIENTS AND THEIR FAMILIES. GROUPS ARE GUIDED BY ONCOLOGY HEALTH PROFESSIONALS, PROVIDING INFORMATION AND SUPPORT AND ENCOURAGING GREATER COMMUNICATION AMONG PATIENTS, FAMILIES, FRIENDS AND HEALTHCARE PROFESSIONALS. LLS SUPPORT GROUPS ARE THE PERFECT PLACE TO TALK WITH OTHER PEOPLE AFFECTED BY BLOOD CANCERS, INCLUDING PATIENTS, FAMILY MEMBERS AND CAREGIVERS. THE GROUPS PROVIDE MUTUAL SUPPORT AND OFFER THE OPPORTUNITY TO DISCUSS ANXIETIES AND CONCERNS WITH OTHERS WHO SHARE THE SAME EXPERIENCES. THIS SHARING STRENGTHENS THE FAMILY BOND AND ENHANCES EVERYONE'S ABILITY TO COPE WITH CANCER. IN ADDITION, LLS ALSO HOSTED 7 ONLINE NATIONAL CHAT GROUPS - I.E., VIRTUAL SUPPORT GROUPS - THAT ARE PROFESSIONALLY MODERATED. IN FY 2019, 3,817 INDIVIDUALS PARTICIPATED IN THESE CHATS. PATTI ROBINSON KAUFMANN FIRST CONNECTION PROGRAM: FIRST CONNECTION IS A PROGRAM THAT LINKS NEWLY DIAGNOSED PATIENTS AND CAREGIVERS TO A PEER VOLUNTEER WHO HAS EXPERIENCED A SIMILAR DIAGNOSIS. A TRAINED PATIENT/CAREGIVER- VOLUNTEER CURRENTLY IN REMISSION CONTACTS THE PATIENT/CAREGIVER TO SHARE INFORMATION AND SUPPORT. THIS PROGRAM IS AVAILABLE THROUGH LLS CHAPTERS; REFERRAL IS ALSO PROVIDED BY LLS'S INFORMATION RESOURCE CENTER. -OVER 1,500 FIRST CONNECTIONS WERE MADE ACROSS THE US IN FY 2019 FORM 990, PAGE 2, PART III, LINE 4C C) PUBLIC HEALTH EDUCATION: INFORMATION AND EDUCATION. PAYING FOR MEDICAL CARE, MAKING TREATMENT CHOICES, COMMUNICATING WITH HEALTHCARE PROVIDERS, FAMILY MEMBERS AND FRIENDS-THESE ARE SOME OF THE STRESSES THAT COME WITH A CANCER DIAGNOSIS. LLS'S INFORMATION SPECIALISTS ARE MASTER'S LEVEL ONCOLOGY SOCIAL WORKERS, NURSES AND HEALTH EDUCATORS WHO PROVIDE HELP WITH DISEASE, TREATMENT AND CLINICAL TRIAL INFORMATION AND SUPPORT. INFORMATION SPECIALISTS MAY ALSO REFER PATIENTS AND CAREGIVERS TO A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER. THE NURSES IN THIS CENTER HAVE EXPERTISE IN THE BLOOD CANCERS AND PROVIDE PATIENTS AND THEIR CAREGIVERS WITH COMPREHENSIVE NAVIGATION TO FIND AND ENROLL IN AN APPROPRIATE CLINICAL TRIAL. AS PART OF THIS PROCESS, THE NURSES WORK CLOSELY WITH INFORMATION SPECIALISTS TO ADDRESS RESOURCE BARRIERS TO CLINICAL TRIAL ENROLLMENT. PATIENTS, FAMILIES AND HEALTHCARE PROFESSIONALS MAY SPEAK TO AN INFORMATION SPECIALIST AT (800) 955-4572 MONDAY THROUGH FRIDAY, 9 A.M. TO 9 P.M., ET, EMAIL INFOCENTER@LLS.ORG OR CHAT ONE-ON-ONE VIA THE LLS WEBSITE. THE INFORMATION RESOURCE CENTER OFFERS TRANSLATION SERVICES IN MORE THAN 165 LANGUAGES. IN FY 2019: - 20,347 INQUIRIES WERE MADE TO OUR INFORMATION SPECIALISTS. - 13,583 HOUSEHOLDS RECEIVED INFORMATION AND/OR SUPPORT FROM INFORMATION SPECIALISTS VIA EMAILS, PHONE, AND ANSWER CHATS. - 602 PATIENTS WORKED WITH A NURSE IN THE CLINICAL TRIAL SUPPORT CENTER TO RECEIVE COMPREHENSIVE ASSISTANCE WITH CLINICAL TRIAL ENROLLMENT; OVER 20% OF PATIENTS ASSISTED ENROLLED ON A CLINICAL TRIAL. LLS OFFERS PATIENTS AND CAREGIVERS FREE ONE-ON-ONE PHONE AND EMAIL CONSULTATIONS WITH A REGISTERED DIETITIAN WITH EXPERTISE IN ONCOLOGY NUTRITION. THIS SERVICE IS AVAILABLE TO ALL CANCER PATIENTS AND THEIR CAREGIVERS. IN FY 19 NEARLY 900 CONSULTATIONS WERE PROVIDED. THE LLS WEBSITE THE LLS WEBSITE, WWW.LLS.ORG, FULFILLS A WIDE VARIETY OF EDUCATION AND INFORMATION NEEDS. VISITORS CAN PERSONALIZE THEIR WEB PAGES TO THEIR LOCATION TO KEEP CURRENT WITH DISEASE-SPECIFIC UPDATES AND COMMUNITY EDUCATION AND SUPPORT ACTIVITIES. THE WEBSITE PROVIDES ACCESS TO LLS PROGRAMS AND SERVICES, INCLUDING FINANCIAL ASSISTANCE, INFORMATION SPECIALISTS, THE MOST CURRENT AND ACCURATE INFORMATION AND STATISTICS, WEEKLY FACILITATED ONLINE CHATS, NATIONAL TELEPHONE AND WEB EDUCATION PROGRAMS, PUBLICATIONS IN ENGLISH AND SPANISH (AND ADDITIONAL LANGUAGES FOR SELECT MATERIALS), PERSONALIZED CLINICAL TRIAL NAVIGATION BY A REGISTERED NURSE, PERSONALIZED NUTRITION CONSULTATIONS BY A REGISTERED DIETICIAN AND CONTINUING EDUCATION PROGRAMS FOR HEALTHCARE PROFESSIONALS. NATIONAL TELEPHONE/ WEB EDUCATION PROGRAMS LLS CONDUCTS TELEPHONE-WEB EDUCATION PROGRAMS FOR PATIENTS, CAREGIVERS, SURVIVORS AND HEALTHCARE PROFESSIONALS ABOUT LEUKEMIA, LYMPHOMA, MYELOMA AND MYELODYSPLASTIC SYNDROMES AS WELL AS SURVIVORSHIP ISSUES. PROGRAM PARTICIPANTS ARE GIVEN THE OPPORTUNITY TO ASK QUESTIONS OF EXPERTS DURING THESE PROGRAMS. ALSO AVAILABLE THROUGH THE LLS WEBSITE ARE VIRTUAL LECTURES AND VIDEOS FEATURING DISEASE-SPECIFIC UPDATES AND INFORMATION ABOUT SUPPORT AND TREATMENT OPTIONS DELIVERED BY WORLD RENOWNED CLINICAL EXPERTS. UPCOMING AND ARCHIVED PROGRAMS ARE POSTED AT WWW.LLS.ORG/WEBCASTS. IN FY 2019: -LLS CONDUCTED 16 LIVE NATIONAL TELEPHONE-WEB EDUCATION PROGRAMS, WITH 10,818 PARTICIPANTS -THERE WERE 29,521 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 2,324 VIRTUAL LECTURE VIEWS; 11,709 PODCAST DOWNLOADS; AND 32,254 VIDEO VIEWS. FORM 990, PAGE 2, PART III, LINE 4D D) PROFESSIONAL EDUCATION: LLS SERVES THE EDUCATIONAL NEEDS OF THE MEDICAL AND RESEARCH COMMUNITY THROUGH A NUMBER OF PROFESSIONAL EDUCATION SYMPOSIA OFFERED THROUGHOUT THE YEAR. THE EDUCATIONAL PROGRAM OFFERS VARYING FORMATS TO FACILITATE THE EXCHANGE OF INFORMATION AND IDEAS ON THE NEWEST DEVELOPMENTS IN CANCER RESEARCH AND TREATMENT. UPCOMING AND ARCHIVED CE/CME PROGRAMS ARE AVAILABLE AT WWW.LLS.ORG/CE. IN FY 2019: -LLS PROVIDED 16 CME/CE-GRANTING IN-PERSON EDUCATIONAL PROGRAMS, WITH 3,660 HEALTHCARE PROFESSIONALS IN ATTENDANCE. -THERE WERE 28,877 PAGE VIEWS FOR ARCHIVED WEB PROGRAMS; 10,602 VIRTUAL LECTURE VIEWS; AND 3,617 ONLINE VIDEO VIEWS FOR PROFESSIONALS. - LLS LAUNCHED A NEW PODCAST "TREATING BLOOD CANCERS" FOR HEALTHCARE PROFESSIONALS. IN ITS' INAUGURAL MONTHS THERE WERE 3,617 DOWNLOADS. FORM 990, PART V, LINE 4B CANADA FORM 990, PAGE 6, PART VI, LINE 4 IN FY2019, THE LLS MANAGEMENT AND THE BOARD OF DIRECTORS AMENDED THE BI- LAWS OF THE LLS TO DO THE FOLLOWING: 1) ELIMINATED ALL CLASS A AND CLASS B MEMBERS. 2) ALLOWED BOARD OF DIRECTOR OFFICERS TO EXCEED THEIR TERM LIMITS FOR SERVING IF APPROVED BY TWO-THIRDS OF THE BOARD. 3) CONSOLIDATED THE FINANCE COMMITTEE AND AUDIT COMMITTEE INTO A SINGLE FINANCE AND AUDIT COMMITTEE 4) CONSOLIDATED VARIOUS OPERATING COMMITTEES. FORM 990, PAGE 6, PART VI, LINE 11B THE FORM 990 WAS PREPARED BY THE LLS FINANCE DEPARTMENT AND WAS REVIEWED BY THE CFO, VICE PRESIDENT, CONTROLLER, AND KPMG FOR COMMENT AND SUGGESTED REVISIONS. THE FORM 990 WAS THEN PROVIDED TO THE AUDIT COMMITTEE, WHICH IS A COMMITTEE OF THE BOARD OF DIRECTORS. THE AUDIT COMMITTEE REVIEWED THE 990 AND PROVIDED INPUT PRIOR TO FILING. THE FINAL DRAFT FORM 990, AS WILL BE FILED WITH THE IRS, WAS PROVIDED TO THE ENTIRE BOARD OF DIRECTORS PRIOR TO FILING WITH THE IRS. FORM 990, PAGE 6, PART VI, LINE 12C ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES MEMBERS, CHAPTER BOARD MEMBERS, FAMILY SUPPORT GROUP FACILITATORS, AND TNT COACHES ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY ON AN ANNUAL BASIS AND SUBMIT A SIGNED FORM ACKNOWLEDGING THAT THEY HAVE REVIEWED THE POLICY AND DISCLOSED ANY CONFLICTS OF INTEREST. ALL FORMS ARE COLLECTED AND THE AUDIT COMMITTEE REVIEWS ANY FORMS DISCLOSING A POSSIBLE CONFLICT OF INTEREST AND DETERMINES WHETHER OR NOT A CONFLICT EXISTS. PART VI, LINE 12 C: ALL EMPLOYEES, BOARD OF DIRECTORS MEMBERS, BOARD OF REPRESENTATIVES ARE RECUSED FROM ANY DISCUSSION WHERE A CONFLICT OF INTEREST EXISTS. ANY QUESTIONS REGARDING COI WILL GO TO THE AUDIT COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 15A THE EXECUTIVE COMMITTEE COMPRISED OF INDEPENDENT MEMBERS OF THE BOARD OF DIRECTORS REVIEWS, MONITORS, AND APPROVES THE CHIEF EXECUTIVE OFFICER'S PERFORMANCE AND COMPENSATION. IN 2019 THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THEIR COMPENSATION MARKET LEVELS AND SET THE CHIEF EXECUTIVE'S SALARY COMMENSURATELY. THE COMMITTEE MET, APPROVED AND DOCUMENTED THE PROCESS IN THE COMMITTEE MINUTES. FORM 990, PAGE 6, PART VI, LINE 15B IN 2019, THE EXECUTIVE COMMITTEE, THROUGH AN INDEPENDENT THIRD PARTY, OBTAINED A MARKET STUDY COMPRISED OF SIMILAR NOT-FOR-PROFIT ORGANIZATIONS TO REVIEW THE COMPENSATION MARKET LEVELS OF OTHER OFFICERS AND KEY EMPLOYEES AND TO APPROVE THE PRESIDENT AND CEO'S RECOMMENDATIONS ON THEIR COMPENSATION LEVELS. FORM 990, PAGE 6, PART VI, LINE 17 ILLINOIS, INDIANA, KANSAS, KENTUCKY, LOUISIANA, MASSACHUSETTS, MARYLAND, MAINE, MICHIGAN, MINNESOTA, MISSOURI, MISSISSIPPI, NEW HAMPSHIRE, NEW JERSEY, NEW MEXICO, NEBRASKA, NEW YORK, OHIO, OKLAHOMA, OREGON, PENNSYLVANIA, PUERTO RICO, RHODE ISLAND, SOUTH CAROLINA, TENNESSEE, UTAH, VIRGINIA, WASHINGTON, WISCONSIN, WEST VIRGINIA FORM 990, PAGE 6, PART VI, LINE 19 THE LEUKEMIA & LYMPHOMA SOCIETY, INC. MAKES ITS ANNUAL FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC ON ITS WEBSITE AT WWW.LLS.ORG. ITS GOVERNING DOCUMENTS ARE MADE AVAILABLE UPON REQUEST FOR PUBLIC INSPECTION. ANY IDENTIFIED CONFLICTS OF INTEREST ARE DISCLOSED IN THE 990. BEAT AML LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 15691417 8786795 LLS LLS PEDAL INITIATIVE LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY -816049 48420 LLS LLS TAP LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY LLS LLS TAP X4 LLC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 RESEARCH NY 1138000 4680000 LLS THE LLS RESEARCH PROGRAMS INC 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133470494 PART VII DE 501C3 12A LLS INC true THE LLS RESEARCH FOUNDATION 3 INTERNATIONAL DRIVE RYE BROOK NY 10573 133709252 PART VII DE 501C3 12A LLS INC true THE LLS OF CANADA 804 2 LANSING SQUARE TORONTO CA M2J4P8 PART VII CA NA false false false false false false false false false false false false false false false false false true false false LLS CANADA Q 223331 COST SCHEDULE R THE LEUKEMIA & LYMPHOMA SOCIETY OF CANADA CARRIES OUT THE SAME PRIMARY ACTIVITIES AS THE LEUKEMIA & LYMPHOMA SOCIETY, INC., IN CANADA. THE LEUKEMIA SOCIETY RESEARCH PROGRAMS, INC. AND THE LEUKEMIA RESEARCH FOUNDATION, INC. SUPPORT THE ACTIVITIES OF THE LEUKEMIA & LYMPHOMA SOCIETY, INC.